Lenacapavir Doubles One-Year PrEP Persistence vs Daily Pills in PURPOSE 5
GILD sits 44% above its 52-week low of $116.88 on light trading volume (0.2× avg).
Summary
PURPOSE 5 randomized 267 people in the UK and France not currently on PrEP: 85.6% of those on twice-yearly lenacapavir injections stayed persistent through Week 52 versus 46.3% on daily oral F/TDF, a 39.3-point gap that was statistically significant. Nobody on lenacapavir acquired HIV during the year; one infection occurred in the F/TDF arm. This is the first randomized head-to-head showing the long-acting shot keeps people on prevention, which is the commercial argument for Yeztugo against cheap generic daily pills. Safety looked consistent with earlier studies — injection-site nodules in 67.8% and pain in 60.0%, but no lenacapavir discontinuations from adverse events. Data are being presented at HIV Glasgow 2026, and the persistence gap is the number payers and prescribers will weigh as Yeztugo rolls out.
At the time of this announcement, GILD was trading at $167.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $208.1B. The 52-week trading range was $116.88 to $176.58. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.